Abstract

A REVIEW: ANTICANCER SCREENING MODELS

Aafrin G. Jamadar*, Dr. Nilofar S. Naikwade, Zia-Ul-Haque S. Jamadar, Aasiya J. Dadel

ABSTRACT

According to WHO, cancer is second leading cause of death globally and estimated 9.6 million deaths in 2018.In-vitro anticancer screening model are pre-clinical tool for cancer studies. The available anticancer drugs have distinct mechanisms of action which may vary in their effects on different types of normal and cancer cells. Screening methods are routinely and extensively used to reduce cost and time of drug discovery. Both In-vitro, as well as In-vivo models are available for the screening of compounds. A preclinical screening model should have a high sensitivity and reproducibility. Screening methods for the detection of anticancer activity are of importance in order to find solid tumorspecific agents. This screening model give information about the mechanisms of growth inhibition and tumor-cell kill. Recently, its role has changed to that of a service screen supporting the cancer research community. Target-based and cell-based screenings for new anticancer
drugs in the molecular targeting period are methods of identifying more selective anticancer drugs. This review describes the In-vivo and In-vitro screening methods of anticancer preclinical studies.

Keywords: in-vivo models, tumor growth delay. Xenograft, HFA, GEMM, EAC, In-vitro, MTT, MTS, SRB, Tumor model, Brine shrimp assay.